By Nicholas G. Miller

Biogen expects to record a charge of about $222 million in its fourth-quarter results from "acquired in-process research and development, upfront and milestone expense."

The charge is expected to impact adjusted and non-adjusted net income by about $1.26 a share, Biogen said in a securities filing on Wednesday.

The biotechnology company said the expense category includes costs from collaboration and license agreements such as upfront and milestone payments and "premiums on equity securities and asset acquisitions of acquired in-process research and development."

Biogen doesn't forecast these costs given the uncertainty of their amount and timing, it said.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

January 14, 2026 06:40 ET (11:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.